Carboplatin/Pemetrexed

Phase 2Small molecule

UUniversity Hospital, Essen

Carboplatin/Pemetrexed is one of 42 small molecule programs targeting Lung Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Lung CancerRecruiting

Lung CancerPhase 2

Recruiting

Competition

Competitive Landscape

199 competitors in Lung Cancer

#DrugCompanyPhaseTrials

Imfinzi

AstraZeneca

Phase 3

25 2

Beyfortus

BeiGene

Phase 3

10 3

Abraxane

Bristol-Myers Squibb

Phase 3

7 4

Alecensa

Roche

Phase 3

3 5

Zepzelca

Jazz Pharmaceuticals

Phase 3

3 6

DATROWAY

Daiichi Sankyo

Phase 3

2 7

Lynparza

AstraZeneca

Phase 3

2 8

Tarlatamab-Dznl

Amgen

Phase 3

2 9

Ilaris

Novartis

Phase 3

2 10

Verzenio

Eli Lilly

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 2Recruiting

Lung Cancer

NCT06784791

Clinical

Trials by Indication[1]

Lung Cancer1 trial

Preoperative Amivantamab or Amivantamab and Carboplatin/Pemetrexed Treatment in Patients With Resectable Non-small-cell Lung Cancer Harboring Oncogenic EGFR Mutations (NEOpredict-EGFR)

Recruiting·UUniversity Hospital, Essen·Phase 2·NCT06784791·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Carboplatin/Pemetrexed. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Carboplatin/Pemetrexed compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Carboplatin/Pemetrexed. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University Hospital, Essen company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: UUniversity Hospital, Essen

Carboplatin/Pemetrexed

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Lung Cancer1 trial

References

Drug Info

Quick Facts

Related News